Multimodal therapy for the treatment of nonmetastatic XXXX .

@entity1 @entity2828 @entity5 @entity2879 @entity3 @entity1260
The purpose of this study was to evaluate the outcome of @entity1 with @entity2828 ( @entity2828 ) of the pelvis, attempting to identify prognostic factors to select @entity1 for more aggressive treatment. Seventy-seven @entity1 with nonmetastatic @entity2828 of the pelvis were treated at Rizzoli Institute between 1979 and 1996. Four different protocols of chemotherapy were used successively. Two protocols consisted of VACAc, and two of VACAc plus @entity1260 and @entity2879 . Local treatment consisted of surgery in 5 @entity1 , radiotherapy in 60, and surgery followed by radiotherapy in 12. Mean follow-up was 11 years (range 5-25 years). Thirty-three @entity1 remained continuously free of disease; 43 relapsed (24 due to @entity3 and 19 to local recurrence and @entity3 ); 1 died of treatment-related complications. The 5- and 10-year event-free survival rates were 45% and 44%, respectively, and the 5- and 10-year overall survival rates were 48 and 44. These results are significantly worse than the ones achieved in 329 contemporary @entity1 with extrapelvic lesions treated with the same protocols of chemotherapy (5- and 10-year event-free survival = 46% vs. 64% and 44% vs. 69%). Thus, despite associated chemotherapy, the outcome of @entity2828 localized in the pelvis remains poor, and new innovative methods for the treatment of this @entity5 are needed.
